By Ahmed Aboulenein WASHINGTON (Reuters) - Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by...
By Stephen Culp NEW YORK (Reuters) - Wall Street extended its winning streak on Monday, rallying to a sharply higher close as investors awaited crucial inflation data that could...
Amgen (NASDAQ:AMGN) is a proven performer with an expansive pipeline Inovio Pharmaceuticals (NASDAQ:INO) Investment in the future of medicine Investing in biotech companies also...
Just as the dog days of summer have very little to do with dogs and everything to do with heat, so went the first week of August in the markets. The emphasis was not on the dogs,...
Stocks surged in July, with the major indexes enjoying their best gains since 2020. But the market is still off substantially for the year. The rally came despite the Federal...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
|Average||249.75 (+9.59% Upside)|
|No. of Analysts||22|